Is immunotherapy in the future of therapeutic management of sarcomas?

Research output: Contribution to journalReview articlepeer-review


Sarcomas are rare, ubiquitous and heterogeneous tumors usually treated with surgery, chemotherapy, target therapy, and radiotherapy. However, 25–50% of patients experience local relapses and/or distant metastases after chemotherapy with an overall survival about 12–18 months. Recently, immuno-therapy has revolutionized the cancer treatments with initial indications for non-small cell lung cancer (NSCLC) and melanoma (immune-checkpoint inhibitors).Here, we provide a narrative review on the topic as well as a critical description of the currently available trials on immunotherapy treatments in patients with sarcoma. Given the promising results obtained with anti-PD-1 monoclonal antibodies (pembrolizumab and nivolumab) and CAR-T cells, we strongly believe that these new immunotherapeutic approaches, along with an innovative characterization of tumor genetics, will provide an exciting opportunity to ameliorate the therapeutic management of sarcomas.

Original languageEnglish
Article number173
JournalJournal of Translational Medicine
Issue number1
Publication statusPublished - Dec 2021


  • Anti-cancer vaccine
  • CAR-T therapy
  • Immunotherapy
  • Osteosarcoma
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Is immunotherapy in the future of therapeutic management of sarcomas?'. Together they form a unique fingerprint.

Cite this